Author

Hussein Fadlallah

Observed institution: Hôpital Santa Cabrini

OpenAlex ID: A5113936509

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

2019 · Kausik K Ray, Helen M Colhoun, et al. · The Lancet Diabetes & Endocrinology · 315

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

2021 · Gregory G. Schwartz, Gregory G. Schwartz, et al. · Journal of the American College of Cardiology · 148

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

2022 · Emil Hagström, P. Gabriel Steg, et al. · Circulation · 118

Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment

2021 · Gregory G. Schwartz, Michael Szarek, et al. · Diabetes Care · 40

Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Coronary Syndrome on High-Intensity Statin Therapy: An Analysis of the Placebo Arm of ODYSSEY OUTCOMES

2025 · P. Gabriel Steg, Michael Szarek, et al. · Circulation · 26

Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation

2024 · Shaun G Goodman, Philippe Gabriel Steg, et al. · European Heart Journal - Cardiovascular Pharmacotherapy · 25

Physiologically Guided Thrombolysis in Pulmonary Embolism

2024 · Philippe Rola, Michael Pratte, et al. · Journal of Endovascular Resuscitation and Trauma Management

Works count: 7

Citation count: 671

H-index: 6

I10-index: 6